KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Other Non-Current Liabilities (2019 - 2025)

Esperion Therapeutics' Other Non-Current Liabilities history spans 7 years, with the latest figure at $8.7 million for Q4 2025.

  • For Q4 2025, Other Non-Current Liabilities changed N/A year-over-year to $8.7 million; the TTM value through Dec 2025 reached $8.7 million, changed N/A, while the annual FY2025 figure was $8.7 million, N/A changed from the prior year.
  • Other Non-Current Liabilities reached $8.7 million in Q4 2025 per ESPR's latest filing, up from $7.4 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $265.0 million in Q3 2022 to a low of $1.3 million in Q3 2021.
  • Average Other Non-Current Liabilities over 5 years is $176.9 million, with a median of $228.1 million recorded in 2021.
  • Peak YoY movement for Other Non-Current Liabilities: crashed 99.19% in 2021, then skyrocketed 20446.36% in 2022.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $245.7 million in 2021, then decreased by 10.95% to $218.8 million in 2022, then rose by 9.64% to $240.0 million in 2023, then decreased by 1.48% to $236.4 million in 2024, then tumbled by 96.3% to $8.7 million in 2025.
  • Per Business Quant, the three most recent readings for ESPR's Other Non-Current Liabilities are $8.7 million (Q4 2025), $7.4 million (Q3 2025), and $7.4 million (Q2 2025).